Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch 1 signaling pathway

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 231-243

  Wang, Xing ^a   Zhang, Juan ^b   Zhou, Liang ^c   Sun, Wei ^a   Zheng, Zhi Gang ^a   Lu, Peng ^a   Gao, Yuan ^a   Yang, Xi Sheng ^a   Zhang, Zhuo Chao ^a   Tao, Kai Shan ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Third Internal Medicine Department   (China)

^c The 155 Central Hospital of PLA   (China)

Author keywords

Fbxw7; Hepatocellular carcinoma; Invasion; Migration; Notchl

Indexed keywords

F BOX AND WD REPEAT DOMAIN CONTAINING 7 PROTEIN; GELATINASE A; GELATINASE B; MESSENGER RNA; NOTCH1 RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UROKINASE; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR INVASION; AGED; CELL MOTION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; F-BOX PROTEINS; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 84931083259     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2981     Document Type: Article

References (68)

1. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 6: 674-687, 2006.
2. Villanueva A, Savic R and Llovet JM: Lymphotoxins: New targets for hepatocellular carcinoma. Cancer Cell 16: 272-273, 2009.
3. Wang Z, Inuzuka H, Fukushima H., Wan L, Gao D, Shaik S., Sarkar FH and Wei W: Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep 13: 36-43, 2012.
4. Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93, 2008.
5. Wang Z, Inuzuka H, Zhong J., Wan L, Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett 586: 1409-1418, 2012.
6. Koepp DM, Schaefer LK, Ye X, Keyomarsi K., Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294: 173-177, 2001.
7. Welcker M, Orian A, Jin J., Grim JE, Harper JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085-9090, 2004
8. Wu G, Lyapina S, Das I., Li J, Gurney M, Pauley A., Chui I, Deshaies RJ and Kitajewski J: SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol 21: 7403-7415, 2001.
9. Tu K, Zheng X, Yin G., Zan X, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. Mol Med Rep 6: 525-530, 2012.
10. Nateri AS, Riera-Sans L, Da Costa C and Behrens A: The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303: 1374-1378, 2004
11. Mao JH, Kim IJ, Wu D, Climent J., Kang HC, Del Rosario R and Balmain A: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 1499-1502, 2008.
12. Inuzuka H, Shaik S, Onoyama I., Gao D, Tseng A, Maser R.S., Zhai B., Wan L, Gutierrez A, Lau AW, et al.: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471: 104-109, 2011.
13. Cheng Y and Li G: Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev 31: 75-87, 2012.
14. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al.: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012, 2007
15. Onoyama I, Suzuki A, Matsumoto A., Tomita K, Katagiri H, Oike Y., Nakayama K and Nakayama KI: Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest 121: 342-354, 2011.
16. Maser RS, Choudhury B, Campbell P.J., Feng B., Wong KK, Protopopov A, O' Neil J, Gutierrez A, Ivanova E, Perna I, et al.: Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971, 2007
17. Lee JW, Soung YH, Kim H.J., Park WS, Nam SW, Kim SH, Lee J.Y., Yoo NJ and Lee SH: Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 42: 2369-2373, 2006.
18. Kemp Z, Rowan A, Chambers W., Wortham N, Haiford S, Sieber O., Mortensen N, von Herbay A, Günther T, Ilyas M, et al.: CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res 65: 11361-11366, 2005
19. Hubalek MM, Widschwendter A, Erdel M., Gschwendtner A, Fiegl HM, Müller HM, Goebel G., Mueller-Holzner E, Marth C, Spruck CH, et al.: Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 23: 4187-4192, 2004
20. Koh MS, Ittmann M, Kadmon D., Thompson TC and Leach FS: CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 5: 78-83, 2006.
21. Li J, Guo Y, Liang X., Sun M, Wang G, De W and Wu W: MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4 J Cancer Res Clin Oncol 138: 763-774, 2012.
22. Cheng Y, Chen G, Martinka M., Ho V and Li G: Prognostic significance of Fbw7 in human melanoma and its role in cell migration. J Invest Dermatol 133: 1794-1802, 2013.
23. Imura S, Tovuu LO, Utsunomiya T, Morine Y., Ikemoto T, Arakawa Y, Kanamoto M., Iwahashi S, Saito Y, Takasu C, et al.: The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol 29: 1822-1829, 2014.
24. Tu K, Zheng X, Zan X., Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res 42: 904-910, 2012.
25. Wang Z, Banerjee S, Li Y., Rahman KM, Zhang Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778-2784, 2006.
26. Yu B, Wei J, Qian X., Lei D, Ma Q and Liu Y Notchl signaling pathway participates in cancer invasion by regulating MMPs in lingual squamous cell carcinoma. Oncol Rep 27: 547-552, 2012.
27. Wang J, Fu L, Gu F and Ma Y Notchl is involved in migration and invasion of human breast cancer cells. Oncol Rep 26: 1295-1303, 2011.
28. Zhou L, Wang DS, Li Q.J., Sun W., Zhang Y and Dou KF: Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncol Rep 28: 874-882, 2012.
29. Zhou L, Zhang N, Song W., You N, Li Q, Sun W., Zhang Y, Wang D and Dou K: The significance of Notchl compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One 8: e57382, 2013.
30. Aydin IT, Melamed RD, Adams S.J., Castillo-Martin M, Demir A, Bryk D., Brunner G, Cordon-Cardo C, Osman I, Rabadan R, et al.: FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst 106: djul07, 2014
31. Barnes DM, Harris WH, Smith P, Millis RR and Rubens RD: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74: 1445-1451, 1996.
32. Zhou L, Zhang N, Li Q.J., Sun W., Zhang Y, Wang DS and Dou KF: Associations between high levels of Notchl expression and high invasion and poor overall survival in hepatocellular carcinoma. Tumour Biol 34: 543-553, 2013.
33. Yokobori T, Mimori K, Iwatsuki M., Ishii H, Onoyama I, Fukagawa T., Kuwano H, Nakayama KI and Mori M: p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794, 2009
34. Iwatsuki M, Mimori K, Ishii H., Yokobori T, Takatsuno Y, Sato T., Toh H, Onoyama I, Nakayama KI, Baba H, et al.: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int J Cancer 126: 1828-1837, 2010.
35. Hagedorn M, Delugin M, Abraldes I., Allain N, Belaud-Rotureau MA, Turmo M, Prigent C., Loiseau H, Bikfalvi A and Javerzat S: FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div 2: 9, 2007
36. Zhou ZY, Tu KS, Zhang J, Zheng X., Gao J, Yao YM and Liu QG: Expression of Fbxw7 and its correlation with cell proliferation in human hepatocellular carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue ZaZhi 28: 1303-1306, 2012 (In Chinese).
37. Jandke A, Da Costa C, Sancho R, Nye E., Spencer-Dene B and Behrens A: The F-box protein Fbw7 is required for cerebellar development. Dev Biol 358: 201-212, 2011.
38. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science 284: 770-776, 1999
39. Bedogni B, Warneke JA, Nickoloff B.J., Giaccia AJ and Powell MB: Notchl is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118: 3660-3670, 2008.
40. Blair SS: Notch signaling: Fringe really is a glycosyltransferase. Curr Biol 10: R608-R612, 2000.
41. Minella AC and Clurman BE: Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 4: 1356-1359, 2005
42. Lai EC: Protein degradation: Four E3s for the notch pathway. Curr Biol 12: R74-R78, 2002.
43. Oberg C, Li J, Pauley A., Wolf E, Gurney M and Lendahl U: The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 276: 35847-35853, 2001.
44. Sun L, Hui AM, Su Q, Vortmeyer A., Kotliarov Y, Pastorino S, Passaniti A., Menon J, Walling J, Bailey R, et al.: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287-300, 2006.
45. D'Errico M., de Rinaldis E, Blasi MF, Viti V, Falchetti M., Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, et al.: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 45: 461-469, 2009
46. Landi MT, Dracheva T, Rotunno M., Figueroa JD, Liu H, Dasgupta A, Mann F.E., Fukuoka J., Harnes M, Bergen AW, et al.: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 3: e1651, 2008.
47. Curtis C, Shah SP, Chin S.F., Turashvili G., Rueda OM, Dunning MJ, Speed D, Lynch A.G., Samarajiwa S., Yuan Y, et al.; METABRIC Group: The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486: 346-352, 2012.
48. Su BH, Qu J, Song M., Huang XY, Hu XM, Xie J, Zhao Y., Ding LC, She L, Chen J, et al.: NOTCHl signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma. Oncotarget 5: 6885-6895, 2014
49. Reedijk M, Odorcic S, Chang L., Zhang H, Miller N, McCready D.R., Lockwood G and Egan SE: High-level coexpres-sion of JAG1 and NOTCHl is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537, 2005
50. Chu D, Li Y, Wang W., Zhao Q, Li J, Lu Y., Li M, Dong G, Zhang H, Xie H, et al.: High level of Notchl protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 17: 1337-1342, 2010.
51. Itoh Y and Nagase H: Matrix metalloproteinases in cancer. Essays Biochem 38: 21-36, 2002.
52. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006.
53. Kato Y, Yamashita T and Ishikawa M: Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 9: 565-569, 2002.
54. Giambernardi TA, Grant GM, Taylor G.P., Hay RJ, Mäher VM, McCormick JJ and Klebe RJ: Overview of matrix metallopro-teinase expression in cultured human cells. Matrix Biol 16: 483-496, 1998.
55. Iwasaki M, Nishikawa A, Fujimoto T., Akutagawa N, Manase K, Endo T., Yoshida K, Maekawa R, Yoshioka T and Kudo R: Anti-invasive effect of MMI-166, a new selective matrix metal-loproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 85: 103-107, 2002.
56. Komatsu K, Nakanishi Y, Nemoto N., Hori T, Sawada T and Kobayashi M: Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21: 105-112, 2004
57. Köhrmann A, Kammerer U, Kapp M., Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9: 188, 2009
58. Behrendt N, Rønne E and Danø K: The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 376: 269-279, 1995
59. Skrzydlewska E, Sulkowska M, Koda M and Sulkowski S: Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11: 1251-1266, 2005
60. Mason SD and Joyce JA: Proteolytic networks in cancer. Trends Cell Biol 21: 228-237, 2011.
61. Shimizu M, Cohen B, Goldvasser P., Berman H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res 71: 277-286, 2011.
62. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci 117: 4619-4628, 2004
63. Anand-Apte B, Zetter BR, Viswanathan A, Qiu R.G., Chen J., Ruggieri R and Symons M: Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J Biol Chem 272: 30688-30692, 1997.
64. Duncia JV, Santella JB III, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, et al.: MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 8: 2839-2844, 1998.
65. Webb DJ, Nguyen DH and Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 113: 123-134, 2000.
66. Klemke RL, Cai S, Giannini A.L., Gallagher PJ, de Lanerolle P and Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481-492, 1997
67. Cheng YC, Chen LM, Chang M.H., Chen WK, Tsai FJ, Tsai CH, Lai T.Y., Kuo WW, Huang CY and Liu CJ: Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 325: 15-23, 2009
68. Arai K, Lee SR and Lo EH: Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43: 254-264, 2003.